BioFactura

BioFactura is a biotechnology company headquartered in Frederick, Maryland. The company employs 34 people and has generated $8.3 million in revenue. BioFactura specializes in the development and commercialization of biodefense drugs, novel drugs, and biosimilars. These products are created using the company's patented StableFast™ Biomanufacturing Platform, a technology designed to accelerate the development and manufacture of high-quality drugs at a reduced cost. BioFactura's portfolio includes biodefense solutions against smallpox and Ebola, as well as novel therapies for cancer and cost-effective biosimilars for autoimmune and infectious diseases. The company's StableFast™ Biomanufacturing Platform is a key differentiator, enabling BioFactura to bring life-saving medicines to market more quickly and efficiently. The platform's speed, cost-effectiveness, and superior quality contribute to BioFactura's ability to provide innovative solutions for a range of medical needs. For more information about BioFactura and its products, visit www.biofactura.com.